Prescription drug spending continues to be one of the fastest-growing cost drivers in employer-sponsored health plans. While many organizations have relied on traditional Pharmacy Benefit Managers (PBMs) for years to negotiate pricing and manage formularies, employers are increasingly questioning whether the conventional rebate-based approach is truly delivering the best financial outcomes.
For many self-funded employers, the challenge is no longer simply reducing pharmacy spend. It is understanding where the money is going, identifying hidden inefficiencies, and implementing strategies that improve transparency while still protecting employee access to necessary medications.
As healthcare costs continue to climb, employers are beginning to explore pharmacy cost containment strategies that extend beyond the standard PBM arrangement. Transparent PBMs, carve-out programs, clinical oversight models, and data-driven pharmacy management are becoming important tools in a broader effort to regain control over prescription spending.
Why Traditional PBM Models Are Under Scrutiny
Traditional PBMs were originally designed to help employers negotiate discounts with drug manufacturers and pharmacy networks. Over time, however, the PBM marketplace has become increasingly complex.
Many conventional PBM contracts rely heavily on rebate structures tied to high-cost medications. While rebates can create the appearance of savings, they do not always reduce the actual net cost of care for employers or employees. In some cases, higher-priced drugs generate larger rebates, which can unintentionally incentivize the use of more expensive medications instead of lower-cost alternatives.
In addition, many employers struggle with limited visibility into:
- Spread pricing practices
- Pharmacy network markups
- Specialty drug costs
- Manufacturer rebate retention
- Formulary decision-making
- Utilization trends
As a result, organizations may believe they are receiving competitive pricing while significant hidden costs remain embedded within the pharmacy plan structure.
This growing concern is one reason employers are increasingly evaluating alternative pharmacy management strategies that focus on transparency and measurable outcomes rather than rebate volume alone.
MSI Benefits Group has discussed broader cost-control and forecasting strategies in previous articles, including its insights on benefits budgeting and long-term healthcare planning here: Benefits Budgeting for 2027: Building a More Predictable Cost Strategy
The Rise of Transparent PBM Models
One of the most discussed alternatives in recent years is the transparent PBM model.
Unlike traditional arrangements that may rely on hidden spread pricing or retained rebates, transparent PBMs generally operate on a pass-through pricing structure. This means the employer can see:
- The actual cost paid to pharmacies
- Administrative fees charged by the PBM
- Rebates received from manufacturers
- Exact ingredient costs and dispensing fees
Instead of generating revenue from pricing spreads, transparent PBMs typically charge a clearly defined administrative fee.
For employers, this structure can offer several advantages:
Improved Cost Visibility
Transparent reporting allows plan sponsors to better understand where pharmacy dollars are being spent. This visibility often helps identify unnecessary markups, inflated specialty costs, or underperforming formularies.
Better Contract Accountability
Employers can benchmark pricing more effectively and hold vendors accountable for contractual guarantees and performance metrics.
Greater Flexibility
Some transparent PBMs offer more customizable formularies and network configurations, allowing employers to align pharmacy strategies with the specific needs of their workforce.
That said, transparency alone does not automatically guarantee lower costs. Employers still need strong oversight, careful contract review, and ongoing analytics to ensure pharmacy programs are delivering meaningful savings.
Specialty Drug Management Is Becoming Critical
Specialty medications now represent a disproportionate share of pharmacy spending for many health plans. Although only a small percentage of employees may use specialty drugs, these medications can account for more than half of total pharmacy costs.
This category includes treatments for conditions such as:
- Rheumatoid arthritis
- Multiple sclerosis
- Cancer
- Autoimmune disorders
- Rare genetic diseases
Because specialty medications are often extremely expensive, employers are increasingly exploring carve-out programs and specialized management strategies.
According to the KFF Health Tracking Poll, prescription drug affordability remains one of the most significant healthcare concerns among Americans, placing additional pressure on employers to manage pharmacy costs responsibly.
What Are Pharmacy Carve-Out Programs?
A pharmacy carve-out separates pharmacy benefits management from the broader medical benefits administration structure.
Rather than allowing a single carrier or administrator to manage all aspects of healthcare spending, employers may contract independently with specialized pharmacy vendors or clinical management firms.
These carve-out strategies can include:
- Specialty pharmacy carve-outs
- International sourcing programs
- Clinical prior authorization management
- Independent formulary oversight
- Alternative funding programs
- Manufacturer assistance optimization
The goal is to create a more targeted and data-driven pharmacy management approach that reduces unnecessary spending while maintaining quality care.
Clinical Management Strategies That Reduce Waste
One of the biggest shifts in pharmacy cost containment is the movement toward clinical oversight instead of purely financial negotiations.
Employers are increasingly recognizing that the most effective savings often come from improving utilization management and clinical appropriateness.
Examples include:
Prior Authorization Programs
These programs ensure that high-cost medications meet evidence-based criteria before approval.
Step Therapy
Employees may be encouraged to try clinically appropriate lower-cost medications before progressing to more expensive treatments.
Medication Adherence Programs
Poor medication adherence can lead to worsening health conditions, increased hospitalizations, and higher long-term costs. Clinical outreach programs can improve treatment compliance while reducing downstream claims expenses.
Site-of-Care Optimization
Some specialty infusions administered in hospitals can often be delivered safely in lower-cost outpatient settings or at home, significantly reducing treatment expenses.
Biosimilar Adoption
As biosimilar medications become more available, employers have opportunities to reduce specialty drug costs without sacrificing clinical effectiveness.
These strategies require strong coordination between PBMs, clinical teams, providers, and employers. However, when implemented correctly, they can create sustainable savings that extend beyond temporary rebate improvements.
Data Analytics Are Driving Smarter Decisions
Modern pharmacy cost management increasingly depends on detailed data analysis.
Employers that rely solely on high-level summary reports may miss critical spending patterns. Advanced analytics can reveal:
- High-cost claimant trends
- Specialty drug utilization spikes
- Geographic prescribing variations
- Opportunities for generic substitution
- Non-adherence risks
- Outlier provider prescribing behaviors
This level of insight allows employers to intervene earlier and build more proactive pharmacy strategies.
Organizations that regularly review pharmacy data alongside medical claims data are often in a better position to identify emerging risks before they significantly impact renewal costs.
MSI Benefits Group has also explored how proactive evaluation and early intervention can improve overall health plan performance in its article on post-Q1 claims analysis here: The Post-Q1 Cost Check: Evaluating Early-Year Health Plan Performance
Key Pharmacy Cost Containment Strategies
Employers Looking Beyond Traditional PBMs Are Focusing On:
- Transparent PBM pricing models
- Specialty pharmacy carve-outs
- Clinical prior authorization management
- Biosimilar adoption strategies
- Site-of-care optimization
- Data-driven pharmacy analytics
- Alternative funding programs
- Improved rebate transparency
- Medication adherence initiatives
- Independent formulary management
Why It Matters
Employers that proactively evaluate pharmacy strategies may reduce unnecessary spending, improve forecasting accuracy, and create more sustainable long-term healthcare cost management.
The Future of Pharmacy Cost Management
Pharmacy benefit management is evolving rapidly. Employers are no longer satisfied with generic annual renewal discussions or opaque rebate guarantees. They want measurable outcomes, clearer reporting, and strategies that align financial stewardship with employee wellbeing.
There is no universal solution for every organization. Some employers may benefit from fully transparent PBMs, while others may achieve better results through targeted carve-outs or enhanced clinical oversight programs. The key is understanding that pharmacy cost management requires continuous evaluation, strategic alignment, and a willingness to challenge outdated models.
As prescription drug spending continues to rise, employers that adopt a more sophisticated and data-driven approach to pharmacy benefits will likely be better positioned to control costs without compromising quality of care.
Bottom Line
Pharmacy costs are becoming too significant to manage with a “set it and forget it” approach. MSI Benefits Group works with employers to evaluate pharmacy benefit strategies, improve cost transparency, and identify opportunities for smarter long-term savings.
If your organization is reviewing PBM performance, exploring carve-out options, or seeking more effective pharmacy cost containment strategies, contact MSI Benefits Group to discuss a customized approach tailored to your workforce and financial goals.